Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Genmab's financial outlook is bolstered by the remarkable performance of its leading product, DARZALEX, which recorded worldwide net sales of $3.9 billion in 4Q25, surpassing previous estimates and reflecting strong growth potential. The anticipated increase in DARZALEX royalties to $722 million in 4Q25, alongside the company's robust balance sheet and profitability, further reinforces confidence in its resilience amid broader biotech sector challenges. Additionally, Genmab's expansive pipeline and the presence of various promising clinical data catalysts position the company favorably for continued success in oncology therapeutics.

Bears say

Genmab faces several significant risks that contribute to a negative outlook on its stock, including slowing sales for its leading product, Darzalex, and the potential failure to secure label extensions for it. Additionally, the negative readout from the Phase 3 EPCORE DLBCL-1 trial regarding Epcoritamab has lowered the likelihood of its approval, thereby impacting future revenue streams. Other risks include lower-than-expected market penetration for new products, failures in clinical trials, and broader macroeconomic risks, all of which further strain investor confidence in Genmab's financial stability.

GMAB has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 7 analysts, GMAB has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.